Glucotrack Inc. reported a net loss of $15.8 million, or $30.1 per share, for the nine months ended September 30, 2025, compared to a net loss of $12.5 million, or $2,868 per share, for the same period in 2024. The increase in net loss was primarily due to higher general and administrative expenses and non-cash fair value changes in derivative liabilities. Marketing and general and administrative expenses were $4.4 million, up from $2.9 million a year earlier. Cash and cash equivalents as of September 30, 2025, were $7.9 million, compared to $5.6 million at December 31, 2024. During the period, Glucotrack secured $3 million in funding through a note purchase agreement and expanded its clinical advisory team. The company plans to submit an Investigational Device Exemption to the FDA for its continuous blood glucose monitor technology in spring 2026.